|
 |
|
|||||||
|
|||||||||
Statements of interest
The following authors have declared a statement of interest concerning papers published in volume 32 of the ERJ.
Statements of interest from previous volumes may be viewed here: volume 31; volume 30; volume 29.
A
Back to Top
T. Abramidze. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
A. Agustí has received an educational grant from GlaxoSmithKline. This study has been supported by an unrestricted educational grant from GlaxoSmithKline (GSK). The fluticasone propionate was kindly provided by GlaxoSmithKline. DOI 10.1183/09031936.00020608
S Albertí has received an educational grant from GlaxoSmithKline. This study has been supported by an unrestricted educational grant from GlaxoSmithKline (GSK). The fluticasone propionate was kindly provided by GlaxoSmithKline. DOI 10.1183/09031936.00020608
H. Alkadhi. The author’s study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
J.A. Anderson is a full-time employee of GlaxoSmithKline and holds shares in the company. DOI: 10.1183/09031936.00161507
J.A. Anderson is a full-time employee of GlaxoSmithKline (Uxbridge, UK) and holds shares in the company. DOI 10.1183/09031936.00135008 and 10.1183/09031936.00123408
S. Andreas was reimbursed for attendance at two workshops on smoking cessation funded by Pfizer® in 2006. DOI: 10.1183/09031936.00109607
I. Annesi-Maesano. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
D. Athanasopoulos. The author’s study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
É. Azoulay has been a consultant for Pfizer and Gilead France. DOI: 10.1183/09031936.00142907
B
Back to Top
G. Bacher is an employee of mondoBIOTECH. The study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
C. Baezner. The author’s study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
S. Baldassarre. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00025308
M. Bando. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
E. Baraldi has received honoraria for lectures from Abbot, GlaxoSmithKline, Merck Sharp & Dohme and Valeas, and reimbursement for attending the ERS Congress from Merck Sharp & Dohme. E. Baraldi’s institution received project funding from Aerocrine. DOI: 10.1183/09031936.00002108
M. Barbier. The author’s study was been supported by an unrestricted educational grant from GlaxoSmithKline (GSK). The fluticasone propionate was kindly provided by GlaxoSmithKline. DOI 10.1183/09031936.00020608
N. Barlow. The author’s study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
E.D. Bateman. In the last 3 years, E.D. Bateman has: provided consultancy services for Kyowa Hakko and GlaxoSmithKline; served on advisory boards for Almirall, Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffman le Roche, Kyowa Hakko, Merck, Nycomed, Pfizer and Sanofi-Aventis; received lecture fees from Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Pfizer; served as an expert witness for GlaxoSmithKline; and received industry-sponsored grants from Almirall, Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffman le Roche, Merck, Nycomed, Pfizer, Sanofi-Aventis and Lilly. DOI: 10.1183/09031936.00155307
R.A. Baumgartner. The author’s study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
J. Behr. The author’s study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
W. Berger. The author’s study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
K.C. Bergmann. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
T. Betsuyaku. The author’s study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
D. Bevec is an employee of mondoBIOTECH. The author’s study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
H. Bisgaard has been a consultant to and paid lecturer for Aerocrine, AstraZeneca, Altana, GlaxoSmithKline, Merck, MedImmune, NeoLab and Pfizer. The Danish Paediatric Asthma Centre has received unrestricted institutional grants from Aerocrine, AstraZeneca, GlaxoSmithKline, Merck and MedImmune. H. Bisgaard does not hold stock or options in any pharmaceutical company. DOI: 10.1183/09031936.00002108
B. Björkstén. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
P.N. Black. The author’s study was part funded by Synergenz Bioscience Ltd. DOI : 10.1183/09031936.00093908
F. Blasi reports having received consulting fees from Pfizer, Sanofi-Aventis, and Altana; lecture fees from Bayer, Sanofi-Aventis, Pfizer, Abbott, Altana, and GlaxoSmithKline; and grant support from Pfizer and Altana. The study itself was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
K. Bloch. The ultrasound equipment used in the author’s study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
A.L. Boner has received fees for speaking from GlaxoSmithKline and Merck Sharp & Dohme, a research grant from Merck Sharp & Dohme, and consulting fees from GlaxoSmithKline and Merck Sharp & Dohme. Envicon, a company which produces encasing materials for house dust mite allergen avoidance, belongs to family members. DOI: 10.1183/09031936.00002108
S. Bonini has a research appointment at the Institute of Neurobiology and Molecular Medicine, Italian National Research Council (INMM-CNR, ARTOV), Rome, Italy. He is a member of the Research and Development Commission of the Italian Drug Agency (AIFA), Rome, Italy. He has received research grants, consultancies, editorial activity and honoraria from participation in speakers’ bureaux from the following companies: Alcon, Allergopharma, Allergy Therapeutics, ALK, Almirall, Aventis, AstraZeneca, Bioallergy, Bioxell, GlaxoSmithKline, Lofarma, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi-Synthelabo, Schering-Plough, Stallaergens, UCB, and Zambon. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
R. Borie. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
L. Borish has received a medical school research grant from GlaxoSmithKline and consulting fees from Genentech/Novartis. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
L-P. Boulet. In the last 3 years, L-P. Boulet has: served on advisory boards for AstraZeneca, Altana, GlaxoSmithKline, Merck Frosst and Novartis; received lecture fees from 3M, Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst and Novartis; and received industry-sponsored grants from AstraZeneca, GlaxoSmithKline, Merck Frosst, Schering, Boehringer Ingelheim, Asthma Tx, Ception, Topigen and Alexion. DOI: 10.1183/09031936.00155307
L-P. Boulet has been a member of advisory boards for AstraZeneca, Altana, GlaxoSmithKline, Merck Frosst and Novartis. He has also received: lecture fees from 3M, Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst and Novartis; sponsorship for investigator-generated research from AstraZeneca, GSK, Merck Frosst and Schering; research funding for participating in multicentre studies from 3M, Altana, AsthmaTx, AstraZeneca, Boehringer-Ingelheim, Dynavax, Genentech, GlaxoSmithKline, IVAX, MedImmune, Merck Frosst, Novartis, Roche, Schering, Topigen and Wyeth; and support for the production of educational materials from AstraZeneca, GlaxoSmithKline and Merck Frosst. L-P. Boulet has acted as: an advisor for the “Conseil du Médicament du Québec” Member of the Quebec Workmen Compensation Board Respiratory Committee; Chair of the Canadian Thoracic Society Guidelines Dissemination and Implementation Committee; and co-leader of the Therapeutics Theme of the Canadian AllerGen Network of Centers of Excellence. The author has also been the holder of the Laval University Chair on knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health, as well as a member of the asthma committee of the World Allergy Organisation. DOI: 10.1183/09031936.00109308
H.A. Boushey. In the last 3 years, H.A. Boushey has: served on advisory boards for GlaxoSmithKline; received lecture fees from GlaxoSmithKline, Genentech, Novartis and Boehringer Ingelheim; provided consultancy services for Altana, Sanofi-Aventis, Boehringer-Ingelheim, Novartis, Theravance, Nonomix and Sumitomo; and received an industry-sponsored grant from GlaxoSmithKline. DOI: 10.1183/09031936.00155307
P.L.P. Brand has received, between 2002 and 2007, grants and fees for organising, attending and speaking at symposia, research and consultancy, and employing junior staff members from AstraZeneca, GlaxoSmithKline, Merck and Altana. DOI: 10.1183/09031936.00002108
P.L.P. Brand. The author’s study was supported by an unrestricted educational grant from AstraZeneca (Zoeteermeer, The Netherlands). AstraZeneca had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. DOI 10.1183/09031936.00148107
M. Brauer has served as an expert witness on behalf of an individual whose asthma was affected by exposure to smoke from agricultural burning. DOI: 10.1183/09031936.00097707
C.E. Brightling has received a total of £1 million research funding over the last 3 years (or is pending) from AstraZeneca, Cambridge Antibody Technology, GlaxoSmithKline. C.E. Brightling has also received <£10,000 per annum from consultancy fees from Cambridge Antibody Technology, AstraZeneca, GlaxoSmithKline, Roche, and Pfizer, and participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, MSD, Pfizer). DOI: 10.1183/09031936.00056108
A.F.J. Brouwer. The author’s study was supported by an unrestricted educational grant from AstraZeneca (Zoeteermeer, the Netherlands). AstraZeneca had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. DOI 10.1183/09031936.00148107
B. Brunekreef. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
H.P. Brunner-La Rocca. The ultrasound equipment used in the author’s study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
A. Bruno. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
V. Brusasco received: €11,625 for serving on an advisory board for Byk Goulden in 2003; €11,625 in 2004, €6,250 in 2005 and €3,800 in 2006 for serving on an advisory board for Altana; €5,000 in 2003, €3,000 in 2004, and €3,000 in 2005 from Lofarma for consultancies; €812 in 2003 for speaking in a symposium and €3,750 in 2004 from MSD for consultancy; €6,000 in 2004, €11,500 in 2005, €8,325 in 2006 and €2,500 in 2007 for speaking at conferences sponsored by Boehringer Ingelheim; £960 in 2006 from GSK for participating in an advisory board; €6,000 in 2006 and €3,000 in 2007 from Almirall for serving in an advisory board; €3,000 in 2006 from Forest Laboratories for serving in an advisory board. V. Brusasco’s institution received €20,000 in 2006 as an unrestricted research grant from Boehringer Ingelheim and participated in several multicentre clinical trials financed by pharmaceutical companies (Chiesi, MSD, Boehringer Ingelheim, GSK, Novartis). DOI: 10.1183/09031936.00056808
M. Brutsche. The author’s investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved in: the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
G. Büchele. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
A. Bulfoni reports having received: consulting fees from Sanofi-Aventis and Pfizer; lecture fees from Guidoff; and grant support from Pfizer, Sanofi-Aventis and Wyeth-Lederle. The author's study was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
J.A. Burgers is a member of an advisory board of Roche Netherlands, and travel to the World Conference on Lung Cancer in Seoul was funded by Roche Netherlands. DOI 10.1183/09031936.00165607
P. Burney has received lecture fees from AstraZeneca and is currently advising GlaxoSmithKline on the design of a study. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
P. Burney has received speaking fees from AstraZeneca. DOI: 10.1183/09031936.00155607
D.M. Burns has testified against the tobacco industry in Litigation. DOI: 10.1183/09031936.00160007
A. Bush has received expenses to travel to the ATS and ERS congresses from GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme, Actelion and Altana; he has received fees for chairing (n=1) and speaking (n=1) at ERS Evening Symposia and for lecturing and chairing meetings from GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme and Chiron (no single fee exceeded 2,000 Euros). His department has benefited from travel grants for research fellows from Chiron and GlaxoSmithKline, and received research grants, in all cases administered through the Royal Brompton Hospital Research Department, from Pharmaxis Australia (support of a research fellow), Chiron and Merck Sharp & Dohme. The institutions which employ him (Royal Brompton Hospital and Imperial College, London, UK) benefit from substantial pharmaceutical funding from multiple companies, declared in their own conflict of interest statements. DOI: 10.1183/09031936.00002108
W.W. Busse. In the last 3 years, W.W. Busse has: provided consultancy services for Genetech/Novartis, Isis, GlaxoSmithKline, Altanta, Wyeth, Pfizer, Dynavax, Centocor, Johnson & Johnson, CV Therapeutics, Hoffman-LaRoche, Ception, Amgen, Alza, Takeda, Mellenium, MAP Pharmaceuticals, Merck, Asthmatic, AstraZeneca, MedImmune, Memory Pharmaceuticals, Altair, PDL BioPharma, Schering Corporation, TEVA and Abbott Laboratories; received lecture fees from Novartis, Merck, AstraZeneca and GlaxoSmithKline; and received industry-sponsored grants from Novartis, Dynavax, Wyeth, Centocor, GlaxoSmithKline, Medicinova, Pfizer, Dey, Astellas, Inflazyme, Ception Therapeutics and Biowa/MedImmune. DOI: 10.1183/09031936.00155307
B.K. Butland (now B.K. Nicholas) owns shares in investment companies and unit trusts that are not restricted from holding shares in the tobacco industry.DOI: 10.1183/09031936.00077207
C
Back to Top
J. Callebert. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
P.M.A. Calverley has led studies supported by GSK, Altana, Roche and Chiesi, and has spoken at meetings supported by these companies and by AstraZeneca. He has served on advisory boards for Pfizer and GSK while his department has received non-product-related funding from GSK. DOI: 10.1183/09031936.00161507
P.M.A. Calverley has led studies supported by GSK, Altana, Roche and Chiesi, and has spoken at meetings supported by these companies and by AstraZeneca. He has served on advisory boards for Pfizer and GSK, while his department has received non-product-related funding from GSK. DOI 10.1183/09031936.00135008 and 10.1183/09031936.00123408
J.D. Campbell has received research grant support from Genentech, Inc. and a pre-doctoral fellowship from Genentech and Novartis. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
A. Carlucci has received reimbursement for attending some international meetings from Resmed. DOI: 10.1183/09031936.00000208
T.B. Casale. In the last 3 years, T.B. Casale has: provided consultancy services for Novartis, Genentech, OSI Pharmaceuticals, Zymo/Genetics; served on advisory boards for Novartis, Genentech, Allux and Capnia; received lecture fees from Merck; and received industry-sponsored grants from Dynavax, Novartis, NIH/NHLBI, Alcon Research, Allergy Therapeutics, Curalogic, Amgen, Allied Research, Genentech, Novartis, Pfizer, Schering and Capnia. DOI: 10.1183/09031936.00155307
J.A. Castro-Rodriguez has received honoraria as a lecturer and speaker in scientific meetings and courses under the sponsorship of Merck Sharp & Dohme, GlaxoSmithKline and Grunenthal, and as consultant for GlaxoSmithKline. DOI: 10.1183/09031936.00002108
M. Cazzola has received fees for speaking and consulting and/or financial support for attending meetings from Abbott, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dey, Encysive, GSK, Menarini Farmaceutici, Novartis, Nycomed, Pfizer and Sanovel Valeas. DOI: 10.1183/09031936.00056808
P. Ceriana has received reimbursement for attending some international meetings from Fisher and Paykel and Resmed and fees for consulting from Airox. DOI: 10.1183/09031936.00000208
P. Chanez. In the last 3 years, P. Chanez has: provided consultancy services for Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi and Schering Plough; served on advisory boards for Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi and Schering Plough; received lecture fees from Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi and Schering Plough; and received industry-sponsored grants from Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi and Schering Plough. DOI: 10.1183/09031936.00155307
A. Chaouat has received fees for speaking at conferences and/or consultations from Actelion Pharmaceuticals, GlaxoSmithKline, and Pfizer. DOI 10.1183/09031936.00015608
W. Chung is an employee of Schering Plough. DOI: 10.1183/09031936.00062307
W.O.C. Cookson. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
C.B. Cooper has received: fees for speaking from Boehringer Ingelheim, Pfizer, AstraZeneca and GlaxoSmithKline; research sponsorship from Boehringer Ingelheim, Forest and GlaxoSmithKline; and consulting fees from Boehringer Ingelheim, Dey and Pfizer. DOI: 10.1183/09031936.00030508
S. Corrao received lecture fees from GlaxoSmithKline and grant support from Pfizer. The author's study was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
S. Costantino. The author's study was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
B. Crestani. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
A. Custovic has received grant support from Asthma UK, Moulton Charitable Trust, the UK Medical Research Council and GlaxoSmithKline, and is on the speakers’ bureau for GlaxoSmithKline, AstraZeneca, UCB Pharma, ALK and Phadia; travel to the American Academy of Asthma, Allergy & Immunology congress was funded by AstraZeneca. DOI: 10.1183/09031936.00002108
D
Back to Top
M. Decramer has received: fees for speaking from Boehringer Ingelheim and Pfizer; research sponsorship from AstraZeneca and GlaxoSmithKline; and consulting fees from Boehringer Ingelheim, Pfizer and GlaxoSmithKline. DOI: 10.1183/09031936.00030508
M. Dehoux. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
J.C. de Jongste. In the last 3 years, J.C. de Jongste has served on advisory boards for GlaxoSmithKline, and has received industry-sponsored grants from Aerocrine, GlaxoSmithKline, Roche, AstraZeneca, Chiron, Transave, Pfizer and Friesland Nutrition. DOI: 10.1183/09031936.00155307
J.C. de Jongste’s department (Erasmus Medical Center, Sophia Children’s Hospital, Rotterdam, the Netherlands) received project funding from Aerocrine, manufacturer of nitric oxide analysers, in 2005 and 2006. DOI: 10.1183/09031936.00132607
J.C. de Jongste has received funds for research. His employer (Dept of Paediatrics, Erasmus University Medical Centre, Sophia Children’s Hospital, Rotterdam, the Netherlands) has accepted research funds from the following companies: Aerocrine, GlaxoSmithKline, Roche, AstraZeneca, Chiron, Transave, Pfizer and Friesland Nutrition. DOI: 10.1183/09031936.00002108
I. De Rudder. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
M. Di Valentino. The author’s investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved in: the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
E.J. Duiverman. The author’s study was supported by an unrestricted educational grant from AstraZeneca (Zoeteermeer, the Netherlands). AstraZeneca had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. DOI 10.1183/09031936.00148107
E
Back to Top
E. Eber has received fees for speaking from AstraZeneca and Merck Sharp & Dohme, and for consulting from AstraZeneca and Merck Sharp & Dohme; travel to several congresses was funded by AstraZeneca, GlaxoSmithKline and Merck Sharp & Dohme. DOI: 10.1183/09031936.00002108
B. Eldh has stocks in excess of £13,000 in Swedisch Match, a global Group with a broad offering of brands in smokefree tobacco products, cigars, pipe tobacco and lights products. DOI: 10.1183/09031936.00121507
R. Ellis. The author’s study was supported by an educational grant from AstraZeneca (Charnwood, UK). DOI: 10.1183/09031936.00125307
P.L. Enright. In the last 3 years, P.L. Enright has provided consultancy services for Pfizer and InterMune. DOI: 10.1183/09031936.00155307
M.J. Epton. The author’s study was part funded by Synergenz Bioscience Ltd. DOI : 10.1183/09031936.00093908
M.L. Everard has received fees for speaking at meetings organised by GlaxoSmithKline, Merck Sharp & Dohme, Astra and Abbott. He has sat on advisory boards for GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme, ML Laboratories, Abott and Novartis. M.L. Everard has received research funding from GlaxoSmithKline, Merck Sharp & Dohme and ML Laboratories. He has had his registration fees, travel and accommodation for attending ERS and ATS meetings paid for by AstraZeneca, Merck Sharp & Dohme, Novartis and GlaxoSmithKline. DOI: 10.1183/09031936.00002108
F
Back to Top
A. Fabre. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
J. Fandrey has received travel reimbursement from the ERS for attending the 5th Lung Science Conference in Taormina, Italy. DOI: 10.1183/09031936.00013408
A.J. Fisher received a clinical fellowship award from GlaxoSmithKline. DOI: 10.1183/09031936.00110807
W. Fokkens. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
F. Forastiere. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
U. Frey received reimbursement for travel arrangements to congresses and fees for talks, all of which were within the sponsorship laws of Switzerland. DOI: 10.1183/09031936.00002108
R. Frithiof. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
B.A. Fröhlich. The study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
T. Furukawa. The author's study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
G
Back to Top
G.D. Gamble. The author’s study was part funded by Synergenz Bioscience Ltd. DOI : 10.1183/09031936.00093908
M. Gappa has received an unrestricted medical grant from GlaxoSmithKline and lecture fees (
L. Garcia-Marcos has received reimbursement from GlaxoSmithKline, ALK-Abello and Merck Sharp & Dohme for attending scientific meetings and lecturing at scientific events organised by these industries. He has also consulted for GlaxoSmithKline, Merck Sharp & Dohme and ALK-Abello in the past. DOI: 10.1183/09031936.00002108
S.A. Gauw. The Dept of Pulmonology from the Leiden University Medical Center (Leiden, the Netherlands) received an unrestricted educational grant from AstraZeneca. DOI: 10.1183/09031936.00135907
F. Gejyo. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
J.E. Gern entered into a cooperative research agreement with EraGen Biosciences for the development of the Respiratory MultiCode Assay (viral diagnostic) used in this study. In addition, he has received honoraria for lectures and consulting fees from EraGen, and travel to the Association of Molecular Pathologists Annual Meeting in November 2005 was funded by EraGen. DOI: 10.1183/09031936.00161907
O. Georgiadou. The author’s study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
L. Ghaly is an employee of Pharmacon, PLC, which consults for Schering Plough. DOI: 10.1183/09031936.00062307
H.A. Ghofrani has received educational grants from Pfizer, Actelion and Bayer Schering. H.A. Ghofrani has no stocks or other financial interest in companies that might have any interest or benefit from contents dealt with in this manuscript. H.A. Ghofrani has received lecture fees from: Actelion, Pfizer, Bayer Schering, Encysive and GSK. DOI: 10.1183/09031936.00124007
P.G. Gibson. In the last 3 years, P.G. Gibson has: received lecture fees from AstraZeneca, GlaxoSmithKline and Novartis; received industry-sponsored grants from Pharmaxis and GlaxoSmithKline; and has patents pending with CRC for Asthma, University of Newcastle. DOI: 10.1183/09031936.00155307
M. Gjomarkaj. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
L. Gnatiuc. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
J. Godnic-Cvar. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
S. Golemati. The author’s study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
F. Grimminger has received educational grants from Pfizer, Actelion and Bayer Schering. F. Grimminger has no stocks or other financial interest in companies that might have any interest or benefit from contents dealt with in this manuscript. F. Grimminger has received lecture fees from: Actelion, Pfizer, Bayer Schering, Encysive and GSK. DOI: 10.1183/09031936.00124007
J.G. Grootens. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
H
Back to Top
S. Haag. The author’s study was supported by a research grant from Boehringer Ingelheim (Biberach, Germany). DOI: 10.1183/09031936.00129307
T. Haahtela has received fees for speaking at meetings and consultation fees from AstraZeneca, Berlin Chemi, GlaxoSmithKline, MSD, OrionPharma and ScheringPlough. T. Haahtela has received an unrestricted grant from MSD for a clinical study. DOI: 10.1183/09031936.00062307
M. Hasegawa. The author’s study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
T. Haselkorn has been a paid consultant to Genentech, Inc. since December 2002. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
B.A. Hay. The author’s study was part funded by Synergenz Bioscience Ltd. DOI : 10.1183/09031936.00093908
Y.F. Heijdra. The anonymous disclosure of the data of the primary care diagnostic centre involved in the present study is supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
L. Heinzerling. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
D. Hénin. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
H. Herwald. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
N. Hizawa. The author’s study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
M.O. Hoekstra has received fees for speaking from GlaxoSmithKline and Mead Johnson, he received a research grant from GlaxoSmithKline, and travelled with Mead Johnson to the 2007 annual convention of the American Academy of Asthma, Allergy and Immunology. DOI 10.1183/09031936.00020108
M.M. Hoeper has received lecturer honoraria from Actelion Pharmaceuticals, GSK, Bayer-Schering, Pfizer and Encysive. The author is also a member of the scientific advisory boards for Actelion Pharmaceuticals, Bayer, Pfizer, GSK and Encysive. DOI: 10.1183/09031936.00091908
F. Holguin. The author's study was supported by a research grant from Novartis pharmaceuticals. DOI: 10.1183/09031936.00012408
J. Holme. The author’s study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
R.J. Hopkins. The author’s study was part funded by Synergenz Bioscience Ltd. DOI : 10.1183/09031936.00093908
T. Hosono. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
T. Howes was given a travel grant on two occasions to attend the ERS Congress by Novartis Pharma; was a consultant for Glaxo Welcome on a research programme for a fee of £500; and received fees for commercial research from Boehringer Ingelheim and Novartis Pharma. DOI 10.1183/09031936.00137008
M. Humbert has received consulting fees from Actelion, Myogen and Schering AG, and lecture fees from Actelion, Schering AG, Pfizer and United Therapeutics. DOI: 10.1183/09031936.00009008
I
Back to Top
M.D. Inman. The author’s study was supported by an educational grant from AstraZeneca (Charnwood, UK). DOI: 10.1183/09031936.00125307
I. Iori reports having received consulting fees from Pfizer and lecture fees from GlaxoSmithKline and Sanofi-Aventis. The study itself was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
Y. Ishii. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
Y. Ito. The author’s study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
J
Back to Top
C. Jansen. The ultrasound equipment used in the author’s study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
C. Janson. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
L.J. Janssen. The author’s study was supported by operating funds provided by GlaxoSmithKline of Canada. DOI: 10.1183/09031936.00167007
P. Jones has received, in the last 5 years, one grant of £100k from GSK, lecture and consulting fees from GSK, AstraZeneca, Boehringer, Spriation, Roche, Almirall and Bayer. DOI 10.1183/09031936.00135008 and 10.1183/09031936.00123408
P.W. Jones. Over the last 5 years, P.W. Jones has received a grant of £100,000 from GSK, and lecture and consulting fees from GSK, AZ, Boehringer, Spiration, Roche, Almirall and Bayer. DOI: 10.1183/09031936.00161507
G. Joos. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
U.R. Juergens. The author’s study was supported by a research grant from Boehringer Ingelheim (Biberach, Germany). DOI: 10.1183/09031936.00129307
K
Back to Top
S. Kajikawa. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
O.N. Keene is a full-time employee of GlaxoSmithKline and owns shares in the company. DOI: 10.1183/09031936.00161507
O.N. Keene is an employee of GlaxoSmithKline (Uxbridge, UK) and holds shares in the company. DOI 10.1183/09031936.00135008 and 10.1183/09031936.00123408
S. Keshavjee. The author’s study was supported by operating funds provided by GlaxoSmithKline of Canada. DOI: 10.1183/09031936.00167007
A. Kessel-Schaefer. The ultrasound equipment used in the author’s study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
C. Kitagawa. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
M. Kohler. The ultrasound equipment used in the author’s study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
S. Konno. The author’s study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
A. Koutsoukou. The author’s study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
M.L. Kowalski. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
S. Kriemler. The ultrasound equipment used in the author’s study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
L
Back to Top
T.H. Lam has received free nicotine replacement therapy from Pfizer for research on smoking cessation. He is vice chairman of Hong Kong Council on Smoking and Health. DOI: 10.1183/09031936.00160007
C. Lange has received honoraria for speaking at symposia that were sponsored by Oxford-Immunotec, a manufacturer of an ELISPOT for the immunodiagnosis of tuberculosis. DOI: 10.1183/09031936.00059308
P. Latzin’s travel expenses to the ERS Infant Lung Function course in Nice 2007 were paid by EcoMedics. DOI: 10.1183/09031936.00073608
J-M. Launay. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
J.H. Lee is an employee of Genetech Inc. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
D. Legnani reports having received consulting fees from Sanofi-Aventis, Bayer; lecture fees from Bayer, Sanofi-Aventis, Pfizer, Abbott, and GlaxoSmithKline. The study itself was sponsored by Sanofi-Aventis Italia, Milan, Italy. DOI: 10.1183/09031936.00092607
W. Lenney has received an educational grant for research from GlaxoSmithKline and Abbott Laboratories, been on the Paediatric Advisory Boards of Merck Sharp & Dohme, AstraZeneca, GlaxoSmithKline, Novartis, Altana Pharma and Abbott Laboratories, and received travel funding to the ERS Congress from Novartis and Altana Pharma. In the last 5 years, W. Lenney has received speaker honoraria from Novartis, Altana Pharma, Merck Sharp & Dohme and GlaxoSmithKline. DOI: 10.1183/09031936.00002108
H.H. Leuchte has received a research grant from mondoBIOTECH. The author’s study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
M.L. Levy. In the last 3 years, M.L. Levy has: provided consultancy services for Ranbaxy, Met Office and SCOPUS; served on advisory boards for Trinity Cheisi, Meda Pharmaceuticals and Merck Sharp & Dohme; received lecture fees from AstraZeneca, GlaxoSmithKline, Boehringer/Pfizer, Alk-Abello and Meda; received industry-sponsored grants from Trinity Cheisi, Meda Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Altana, MSD, Boehringer Ingelheim/Pfizer and TEVA Pharmaceuticals; and received royalties from Elsevier Publications. DOI: 10.1183/09031936.00155307
M.A. Lewis has received fees for speaking from GSK, J&J, Pfizer and Philips, fees for consulting from GSK and J&J, and fees for research from GSK, J&J, Pfizer and Philips. DOI: 10.1183/09031936.00096808.
L. Lindbom. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
A. Linka. The author’s investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved in: the collection, analysis and interpretation of data; the writing of the report; or the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
A. Linka. The ultrasound equipment used in the author’s study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
D. Liu is an employee of Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, CT, USA). DOI 10.1183/09031936.00124108
M.C. Liu has received funding from Pfizer for technical training and assays performed in this trial. He has been a paid consultant and participant in advisory boards for Pfizer. He owns stock in Pfizer. The author’s study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
C. Loureiro. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
A.E.M. Lucas. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
M
Back to Top
X. Ma. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
H. Makita. The author’s study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
J. Makowska. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
D.M. Mannino. The author's study was supported by a research grant from Novartis pharmaceuticals. DOI: 10.1183/09031936.00012408
J. Marchal-Sommé. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
S. Marchand-Adam. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
<J.G. Martin has received a medical school grant from Merck in support of this project. DOI 10.1183/09031936.00166907
STRONG>F.J. Martinez has received lecture honoraria from Pfizer, Boehringer Ingelheim and GlaxoSmithKline. F.J. Martinez has received reimbursement for attending advisory boards for Pfizer, Boehringer Ingelheim and GlaxoSmithKline. F.J. Martinez has received consultant fees from ALTANA Pharma, and received honoraria for organising education on behalf of Boehringer Ingelheim and Pfizer. Travel to the ERS Congress was funded by Pfizer. DOI: 01.1183/09031936.00056808
S. Matthiesen. The author’s study was supported by a research grant from Boehringer Ingelheim (Biberach, Germany). DOI: 10.1183/09031936.00129307
G. Mátyás. The author’s study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
K. McGuinness is the inventor on a patent describing the novel methods for cough detection and monitoring, filed by the University Hospital of South Manchester (UK). K. McGuinness has an industrial collaboration and licence agreement with Vitalograph UK Ltd to develop a commercial cough monitoring system (Vitalojak). DOI: 10.1183/09031936.00052008
S. McKenzie has received departmental funds for travel from Allen and Hanburys. She has been an expert witness for both physicians and patients about issues concerning the treatment of asthma in preschool children. DOI: 10.1183/09031936.00002108
S. Menjoge is an employee of Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, CT, USA). DOI 10.1183/09031936.00124108
A. Meyer. The author’s investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved in: the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
A. Michils. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00025308
J. Mittendorf is a full-time employee at Bayer HealthCare. DOI: 10.1183/09031936.00114407
M. Mörgelin. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
K. Mori. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
A. Morice leads the development of the Hull Automated Cough Counter. DOI: 10.1183/09031936.00052008
Z. Mourid. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00025308
N
Back to Top
R. Naeije has received fees for speaking, reimbursements of travel expenses for attending meetings, and research funds from Actelion Pharmaceuticals, Encysive, Schering, Pfizer, Mondobiotech, and United Therapeutics. DOI 10.1183/09031936.00015608
K. Nagai. The author’s study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
H. Nakano has filed a patent entitled “System and method for automated detection of apnea and hypopnea”. The software used in the author's study was related to the patent. The study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
Y. Nasuhara. The author’s study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
S. Nava has received reimbursement for attending some international meetings from Draeger, Breas and Resmed, speaking fees from Respironics and Fisher Paykel and fees for consulting from Airox and Respironics. DOI: 10.1183/09031936.00000208
F. Neukirch has received an unrestricted educational grant from Boehringer Ingelheim. The author’s study was supported by unrestricted grants from Boehringer Ingelheim France (Reims, France) and Pfizer, Inc. Lob Conseil organised the logistics and tracking missing data. Theriamis undertook the data management. There are no relations with the tobacco industry.DOI: 10.1183/09031936.00129507
C. Neurohr. The author’s study was sponsored by mondoBIOTECH, Basel, Switzerland. DOI 10.1183/09031936.00050008
M.S. Niederman received research grants from Nektor and Bayer. He received honoraria and consulting fees in excess of €10,000 from Schering, Bayer, Ortho-McNiel and Merck. DOI: 10.1183/09031936.00039908
S. Nishima. The author's study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
M. Nishimura. The author’s study was supported by research grants from Nippon Boehringer Ingelheim Co., Ltd and Pfizer Japan Inc. DOI: 10.1183/09031936.00115307
P. Norwood. The author’s study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
O
Back to Top
P.M. O’Byrne. In the last 3 years, P.M. O’Byrne has: served on advisory boards for AstraZeneca, GlaxoSmithKline, Nycomed, Topigen and Resistentia; received lecture fees from AstraZeneca, Chiesi, GlaxoSmithKline, Nycomed and Ono Pharma; and received industry-sponsored grants from AstraZeneca, Boehringer, Genentech, GlaxoSmithKline, Medimmune, Nycomed, Topigen and Wyeth. DOI: 10.1183/09031936.00155307
S. Oehmcke. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
T. Oei has received an educational grant from the ResMed Foundation. DOI: 10.1183/09031936.00127507
Y. Ohnishi. The author's study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
S. Ohno. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
M. Oki. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
P
Back to Top
E. Pace. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
M. Pai is an external consultant for the Foundation for Innovative New Diagnostics (FIND, Geneva, Switzerland), a nonprofit agency that collaborates with several industry partners (including Hain LifeScience, Nehren, Germany) for the development of new diagnostics for neglected infectious diseases. FIND had no role in the conduct of this meta-analysis and no industry partner was involved in the preparation of this manuscript. DOI 10.1183/09031936.00061808
P.D. Paré is the principal investigator of a project funded by GlaxoSmithKline to develop CT-based algorithms to quantify emphysema and airway disease in COPD. With collaborators, he has received ~$300,000 to develop and validate these techniques. The funds have been applied solely to the research to support programmes and technicians. P.D. Paré is also the principal investigator of a Merck Frosst supported research programme to investigate gene expression in the lungs of patients who have COPD. He and collaborators have received ~$200,000 for this project. These funds have supported the technical personnel and expendables involved in the project. Neither of these projects relates to the topic of the present article. DOI: 10.1183/09031936.00129107
M.R. Partridge. In the last 3 years, M.R. Partridge has: served on advisory boards for Novartis, AstraZeneca and Chiesi; and received lecture fees from AstraZeneca, Novartis, Merck, GlaxoSmithKline and Cipla. DOI: 10.1183/09031936.00155307
I.D. Pavord. In the last 3 years, I.D. Pavord has: received lecture fees from GlaxoSmithKline and AstraZeneca; has sat on advisory boards for GlaxoSmithKline, AstraZeneca, Merck and Novartis; and has received industry-sponsored grants from GlaxoSmithKline. DOI: 10.1183/09031936.00155307
R. Peché. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00025308
D. Perrotin has served on advisory boards, as speaker in scientific meetings and as study coordinator or investigator for E. Lilly. The author’s study was supported by unrestricted grants from Boehringer Ingelheim France (Reims, France) and Pfizer, Inc. Lob Conseil organised the logistics and tracking missing data. Theriamis undertook the data management. There are no relations with the tobacco industry. DOI: 10.1183/09031936.00129507
G. Piacentini has received funding to attend the ERS Congress from Merck Sharp & Dohme and to attend a 3-day course on medical management at Bocconi University from AstraZeneca. He has received fees for speaking at national meetings and for contribution to educational programmes sponsored by GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme, Valeas and Dompè Pharmaceuticals. DOI: 10.1183/09031936.00002108
R. Pistelli. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
D.S. Postma has received: fees for consulting for GSK, AstraZeneca and ALTANA Pharma; funds for research from ALTANA Pharma, AstraZenca and GSK; fees for speaking from ALTANA Pharma, AstraZeneca and GSK; and reimbursement for attending a symposium from AstraZeneca, ALTANA Pharma and GSK. DOI 10.1183/09031936.0101508
J. Potts. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
S. Provencher has received consulting and lecture fees from Actelion Pharmaceuticals Inc. and Encysive Canada Inc., and consultant fees from Unither Biotech Inc. DOI: 10.1183/09031936.00009008
M.A. Puhan received unrestricted research grants that were deposited into research accounts of the research groups that he belongs to from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca for development of quality of life instruments and respiratory rehabilitation trials. DOI: 10.1183/09031936.00140507
Q
Back to Top
C. Quesnel. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
R
Back to Top
K.F. Rabe has been consulting, participated in Advisory Board Meetings and received lecture fees from AstraZeneca, Boehringer, Chiesi Pharmaceuticals, Pfizer, Novartis, AltanaPharma, MSD and GSK. K.F. Rabe holds no stock or other equities in pharmaceutical companies. The Dept of Pulmonology at Leiden University Medical Center (Leiden, the Netherlands), and thereby K.F. Rabe as head of the department, has received grants from AltanaPharma (US$222,616), Novartis (US$90,640), Bayer (US$61,762), AstraZeneca (US$113,155), Pfizer (US$406,000), MSD (US$118,000), Exhale Therapeutics (US$90,000), Boehringer Ingelheim (US$390,000), Roche (US$120,000) and GSK (US$299,495) in the years 2001 until 2006. The Dept of Pulmonology (Leiden University Medical Center) also received an unrestricted educational grant from AstraZeneca. DOI: 10.1183/09031936.00135907
K. Racké has received reimbursement for attending a symposium. The author’s study was supported by a research grant from Boehringer Ingelheim (Biberach, Germany). DOI: 10.1183/09031936.00129307
H. Rasch. The author’s investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved in: the collection, analysis and interpretation of data; the writing of the report; or the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
L. Rasouliyan is an employee of ICON Clinical Research, a company which receives research funding from Genentech, Inc. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
T. Raupach was reimbursed for attendance at two workshops on smoking cessation funded by Pfizer® in 2006. DOI: 10.1183/09031936.00109607
P. Ravn has served as consultant on the formulation of clinical guidelines. The author received a single payment (€2,000) from Cellestis in 2006 and was an invited speaker at Cellestis-sponsored conferences in 2006 and 2007. DOI: 10.1183/09031936.00125607
H.K. Reddel. In the last 3 years, H.K. Reddel has received consultancy payments from GlaxoSmithKline and AstraZeneca, has served on advisory boards for GlaxoSmithKline and AstraZeneca, and has received lecture fees from AstraZeneca. H.K. Reddel’s employer has received funding from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Pharmaxis. DOI: 10.1183/09031936.00155307
R.J. Riese. The author’s study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
N. Roche has, in the past 5 years, received fees for speaking, organising education or consulting from Altana Pharma, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Pfizer. The author’s study was supported by unrestricted grants from Boehringer Ingelheim France (Reims, France) and Pfizer, Inc. Lob Conseil organised the logistics and tracking missing data. Theriamis undertook the data management. There are no relations with the tobacco industry.DOI: 10.1183/09031936.00129507
R.J. Roorda has been asked to give lectures at several symposia on paediatric pulmonology. On some occasions, he has received a small speaker’s fee. The author’s study was supported by an unrestricted educational grant from AstraZeneca (Zoeteermeer, The Netherlands). AstraZeneca had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. DOI 10.1183/09031936.00148107
G.A. Rossi has received educational grants and fees for speaking and consulting from Novartis, Merck Sharp & Dohme, Abbott, Altana and Valeas. DOI: 10.1183/09031936.00002108
M.D. Rossman has been a paid consultant both to industry and plaintiffs. In addition, he has been deposed as both an expert in chronic beryllium disease and also a treating physician. DOI: 10.1183/09031936.00098408
A.G. Rothfuchs. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
C. Roussos. The author’s study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
C. Ruffié. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
E.W. Russi. The author’s study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
P. Rytilä has received consultation fees and fees for speaking at meetings organised by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline and MSD. P. Rytilä has been employed by Orion Corporation Orion Pharma since January 2007. DOI: 10.1183/09031936.00062307
P. Rzehak. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
S
Back to Top
H. Saka. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
C. Sanjuas. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
T. Schermer has received unrestricted research grants from several pharmaceutical companies and is a member of the International Primary Care Research Group speakers bureau. DOI: 10.1183/09031936.00088007
T.R.J. Schermer has received fees for attending and speaking at international conferences and several unrestricted grants for research from manufacturers of respiratory drugs (GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca). The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study is supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
H.J. Schünemann received unrestricted research grants and honoraria that were deposited into research accounts or received by a research group that he belongs to from Pfizer, AstraZeneca and UnitedBiosource for development or consulting regarding quality of life instruments for chronic respiratory diseases. DOI: 10.1183/09031936.00140507
T. Schürmann. The ultrasound equipment used in the author’s study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
P.F. Schwartz. The author’s study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
M.R. Sears. In the last 3 years, M.R. Sears has: received consultancies from AstraZeneca, GlaxoSmithKline and Merck Frosst; served on advisory boards for AstraZeneca, GlaxoSmithKline and Nycomed; received lecture fees from AstraZeneca, GlaxoSmithKline and Nycomed; served as an expert witness for AstraZeneca, GlaxoSmithKline and Nycomed; received industry-sponsored grants from AstraZeneca and Merck Frosst; and holds an endowed chair jointly supported by AstraZeneca and McMaster University. DOI: 10.1183/09031936.00155307
P. Seddon has received honoraria from Merck Sharp & Dohme for speaking at educational meetings and attending a medical advisory board. DOI: 10.1183/09031936.00002108
O. Selroos has received consultation fees and fees for speaking at meetings organised by AstraZeneca, and has stocks in excess of £5,000 in AstraZeneca. DOI: 10.1183/09031936.00062307
K. Senzaki. The author's study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
S. Shaheen. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
T. Shimokata. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
E.K. Silverman received an honorarium for a talk on COPD genetics in 2006 as well as grant support and consulting fees from GlaxoSmithKline for two studies of COPD genetics. He has also received honoraria from Wyeth, Bayer, and Astra-Zeneca. DOI: 10.1183/09031936.00040208
M. Silverman has received consultancy fees from Merck Sharpe and Dohme, UK. DOI: 10.1183/09031936.00002108
G. Simonneau has serverd on the advisory committees for Actelion, Pfizer, Schering, United Therapeutics and GlaxoSmithKline. DOI: 10.1183/09031936.00009008
O. Sitbon has received consulting fees from Actelion, Myogen and GlaxoSmithKline, and lecture fees from Actelion, Schering AG and Pfizer. DOI: 10.1183/09031936.00009008
L. Skadhauge. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
I.J.M. Smeele. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
J. Smith is the inventor on a patent describing the novel methods for cough detection and monitoring, filed by the University Hospital of South Manchester (UK). J. Smith has an industrial collaboration and licence agreement with Vitalograph UK Ltd to develop a commercial cough monitoring system (Vitalojak). DOI: 10.1183/09031936.00052008
S. Smith has received an educational grant from the ResMed Foundation. DOI: 10.1183/09031936.00127507
O. Soehnlein. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
P. Soler. SB215505, a specific antagonist of the 5-HT2B receptor, was kindly provided by GlaxoSmithKline. MDL100907 and LY266097 were both provided by J. Würch (Roche, Basel, Switzerland). RS127445 was a generous gift from M. McNamara (Syntex, Palo Alto, CA, USA). DOI: 10.1183/09031936.00126907
J. Solway has received or benefitted from research funding from GlaxoSmithKline and from AstraZeneca, and has received consulting fees from Tanox, Merck, Wyeth, Cytokinetics, GlaxoSmithKline, AstraZeneca, Critical Therapeutics and Genentech. DOI 10.1183/09031936.00092908
I.J. Sørensen has received a fee for speaking from Wyeth and Abbott, who both make TNF-α blockers. She also received a fee from Abbott for arranging journal clubs for young doctors, funds for research from Abbott for multicentre studies of patients with spondyloarthritis, and fees for consulting from Abbot and BMS. DOI: 10.1183/09031936.00125607
D. Soussan. The author’s study was supported by unrestricted grants from Boehringer Ingelheim France (Reims, France) and Pfizer, Inc. Lob Conseil organised the logistics and tracking missing data. Theriamis undertook the data management. There are no relations with the tobacco industry. DOI: 10.1183/09031936.00129507
D.S. Southam. The author’s study was supported by an educational grant from AstraZeneca (Charnwood, UK). DOI: 10.1183/09031936.00125307
J-P. Stasch has, in the past 5 years, been employed by an organisation that may in any way gain or lose financially from the results of his study or the conclusions of his review, editorial or letter. DOI: 10.1183/09031936.00114407
P.J. Sterk. The Dept of Pulmonology from the Leiden University Medical Center (Leiden, the Netherlands) received an unrestricted educational grant from AstraZeneca. DOI: 10.1183/09031936.00135907
P.J. Sterk. In the last 3 years, P.J. Sterk has: received lecture fees from GlaxoSmithKline Netherlands and AstraZeneca; received industry-sponsored grants from GlaxoSmithKline Netherlands; and receives royalties from Elsevier Scientific Publishing. DOI: 10.1183/09031936.00155307
A.G. Stewart has received grant support and been reimbursed conference attendance costs by GSK (UK). DOI: 10.1183/09031936.00119307
P.M. Stewart served as an expert witness on the Committee of Safety of Medicine on Inhaled Steroids 2004-2005. The author’s study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
R.A. Stockley has received fees for consultancy as part of an advisory board from GSK, Roche and MSD. Lecture fees have been paid to R.A. Stockley by Talecris and GSK. R.A. Stockley has received industry sponsored grants from AZ, Altana and Talecris, to cover research costs and staff salaries. The author’s study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
S.W. Stoloff. In the last 3 years, S.W. Stoloff: has received consultancy payments from Alcon, Altana, AstraZeneca, Dey, Genentech, GlaxoSmithKline, Merck, Novartis, Sanofi-Aventis, Schering-Plough and Teva; serves on boards or advisory boards for Altana, Alcon, AstraZeneca, Dey, Genentech, GlaxoSmithKline, Novartis, Sanofi-Aventis and Schering-Plough; and has received lecture fees from AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00155307
D. Stolz. The author’s investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved: in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
D. Strachan. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
G. Stratakos. The author’s study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
Y. Sugiyama. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
S. Suissa has participated in advisory board meetings, conferences and as a speaker in scientific meetings by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pirzer and Sepracor and received research grants from AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00108308 and DOI: 10.1183/09031936.00103008
A.L. Sullivan has no financial interest in any company that may be affected by the published study. She has accepted financial assistance in attending national and international conferences and educational meetings from the following: GlaxoSmithKline, AstraZeneca, Altana Pharma (now Nycomed), Merck Sharp Dohme and Boehringer Ingelheim. A.L. Sullivan has received fees from GlaxoSmithKline for speaking at educational meetings. She also received fees for consultancy work from Altana Pharma, on a matter unrelated to the subject of the published study. The author’s study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
B.E. Sullivan. The author’s study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
S.D. Sullivan has received fees for speaking, research funds and consulting honorarium from Genentech, Inc. and Novartis. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
S.D. Sullivan. In the last 3 years, S.D. Sullivan: has received consultancy payments from Genentech, Novartis and Schering-Plough; has served on advisory boards for Merck, Schering-Plough, GlaxoSmithKline and Novartis; and has received industry-sponsored grants from Amgen, Genentech and Novartis. DOI: 10.1183/09031936.00155307
E. Suzuki. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
A. Swensen is an employee of Novartis Pharmaceuticals Corporation. The author's study was supported by a research grant from Novartis pharmaceuticals. DOI: 10.1183/09031936.00012408
S.J. Szefler. In the last 3 years, S.J. Szefler: has served on advisory boards for AstraZeneca, GlaxoSmithKline, Merck, Genentech, Novartis, Verus, MAP and Schering; has received lecture fees from Merck; and has received industry-sponsored grants from Ross, Division of Abbott. DOI: 10.1183/09031936.00155307
T
Back to Top
S. Tajima. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
T. Takada. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
M. Tamm. The author’s investigator-driven study was supported by an unrestricted grant from Actelion Pharma Schweiz AG. The company was not involved: in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. K. Bögl and K. Bruppacher (Medical Department, Actelion Pharma AG, Baden, Switzerland) provided logistical support. DOI: 10.1183/09031936.00011308
S. Tanaka. The prototype thin bronchoscope was loaned to the manuscript authors by Olympus Ltd (Tokyo, Japan) for the duration of the study. None of the authors of the manuscript has any financial stake in Olympus Ltd. DOI: 10.1183/09031936.00169107
T. Tanigawa has filed a patent entitled “System and method for automated detection of apnea and hypopnea”. The software used in the study was related to the patent. T. Tanigawa serves as CEO of the Somnonics Co. Ltd, to develop a screening for sleep apnea syndrome in general population, established by the support of the University of Tsukuba. This study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
D.R. Taylor. In the last 3 years, D.R. Taylor has received lecture fees and an industry-sponsored grant from Aerocrine AB, Solna, Sweden. DOI: 10.1183/09031936.00155307
T. Tazzeo. The author’s study was supported by operating funds provided by GlaxoSmithKline of Canada. DOI: 10.1183/09031936.00167007
J.G. Teeter. The author’s study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
M.D. Thomas. In the last 3 years, M.D. Thomas: has served on advisory boards for GlaxoSmithKline, MSD, Merck Pharmaceutical, Ivax, Altana and Boehringer Ingelheim; has received lecture fees from GlaxoSmithKline, MSD, Merck Pharmaceutical, Ivax, Boehringer Ingelheim and AstraZeneca; and has received industry-sponsored grants from MSD, AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00155307
G. Thomsen. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
V.Ø. Thomsen is employed by the Statens Serum Institut (SSI). The SSI offers the QuantiFERON®-TB Gold analysis for clinical use, distributes the test within the region, and produces tuberculin and the BCG vaccine. V.Ø. Thomsen does not have any personal gain from any of the above. DOI: 10.1183/09031936.00125607
B.P.A. Thoonen. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
D. Thorn is an employee of Novartis Pharmaceuticals Corporation. The author's study was supported by a research grant from Novartis pharmaceuticals. DOI: 10.1183/09031936.00012408
A. Todo-Bom. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
J.W. Tomlinson. The author’s study was funded by Altana Pharma. DOI: 10.1183/09031936.00016908
C. Tuor. The study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
U
Back to Top
H. Uemori. The author's study was sponsored by the company that developed the portable monitor. All of the financial support was used to conduct the study. None of the authors had any income from the company. The authors analysed the data and wrote the paper. DOI: 10.1183/09031936.00130907
V
Back to Top
A. Valiulis has received travel grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Merck Sharp & Dohme for attending annual meetings of the ERS and ATS, as well as honoraria for lectures in satellite symposia of AstraZeneca, BerlinChemie, GlaxoSmithKline and Merck Sharp & Dohme. DOI: 10.1183/09031936.00002108
W.M.C. van Aalderen has received grants for attending symposia from GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme, Altana Pharma, Novartis and Ooms Allergy. He has received speakers’ fees from GlaxoSmithKline, Merck Sharp & Dohme, AstraZeneca, Ivax Pharma, Teva Pharma and Meda Pharma. W.M.C. van Aalderen has received fees for organisation of education from de Baar nascholingen, Benecke nascholingen, Nycomed and Scem Conference Services. He has received unrestricted research grants from GlaxoSmithKline, Merck Sharp & Dohme, AstraZeneca, Ivax Pharma, Teva Pharma and Numico. He has received fees for consulting from AstraZeneca, Merck Sharp & Dohme, Ivax Pharma and Teva pharma. DOI: 10.1183/09031936.00002108
T.J. van Boxem. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
Y. van Durme. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
K. Van Gundy has received funding for participating in a portion of the research used to obtain the data used for this publication. The author’s study was sponsored by Pfizer Inc., who also provided funding for editorial support. DOI: 10.1183/09031936.00129907
A. Van Muylem. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00025308
N. van Rooijen. Clodronate was a gift from Roche (Mannheim, Germany). DOI: 10.1183/09031936.00173207
I.H. van Veen is supported by an unrestricted educational grant from AstraZeneca. DOI: 10.1183/09031936.00135907
C. van Weel has received <$10,000 from AstraZeneca, Bayer and NovoNordisk, and >$10,000 from Boehringer Ingelheim, GlaxoSmithKline and Novartis. DOI: 10.1183/09031936.00088007
C. van Weel is a member of the GOLD Executive. He has received no personal benefits. C. van Weel has received unrestricted research and teaching grants for his university department from AstraZeneca, Bayer, NovoNordisk, Boehringer Ingelheim, GlaxoSmithKline and Novartis. He has no relation to, or income from, the tobacco industry. The anonymous disclosure of the data of the primary care diagnostic centre involved in the author's study was supported by an unrestricted grant from Boehringer Ingelheim. All of the researchers are independent of the funder, Boehringer Ingelheim. DOI: 10.1183/09031936.00170307
T. van Zele. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
S. Varghese is an employee of Schering-Plough. DOI: 10.1183/09031936.00062307
G.M. Verleden is the present holder of the academic grant for Respiratory Pharmacology from the Katholieke Universiteit Leuven, Belgium which is funded by GlaxoSmithKline. DOI: 10.1183/09031936.00134307.
J. Vestbo has received support for research in COPD from GlaxoSmithKline. He has also received honoraria for advisory board activity and presenting at meetings from GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim, Pfizer and Hoffmann-La Roche. J. Vestbo’s wife works in the pharmaceutical industry (AstraZeneca) but neither the author nor his wife own shares in any pharmaceutical company. J. Vestbo received an unrestricted research grant from Scandinavian Tobacco Company of approximately 35,000 Euros in 1985. DOI 10.1183/09031936.00135008 and 10.1183/09031936.00123408
J. Vestbo has received support for research in COPD from GlaxoSmithKline; he has received honoraria for advisory board activities and presenting at meetings from GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim, Pfizer, and Hoffmann-La Roche. J. Vestbo’s wife works in the pharmaceutical industry (AstraZeneca) but neither he nor his wife own shares in any pharmaceutical company. DOI: 10.1183/09031936.00161507
J. Vestbo has received support for research in COPD from GlaxoSmithKline; he has received honoraria for advisory board activity and presenting at meetings from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Pfizer and Hoffmann-La Roche; his wife works in the pharmaceutical industry (AstraZeneca) but neither he nor his wife own shares in any pharmaceutical company. DOI: 10.1183/09031936.00160007
C.M. Villanueva. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
I. Vogiatzis. The author’s study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
E. von Mutius. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
W
Back to Top
J. Wattie. The author’s study was supported by an educational grant from AstraZeneca (Charnwood, UK). DOI: 10.1183/09031936.00125307
E.J.M. Weersink. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
S. Weiland†. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
G. Weinmayr. ALK (Horsholm, Denmark) generously provided reagents for field work in several low-income countries without charge. The Pichincha province (Ecuador) received local funding from the Wellcome Trust. DOI 10.1183/09031936.00157807
I. Weisman is employed by Pfizer Inc., New York, NY, USA. The author’s study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
G. Wennergren has been a paid lecturer for AstraZeneca and Merck, and has received fees for helping AstraZeneca in organising an educational symposium for Swedish paediatric allergists. He does not hold stock or options in any pharmaceutical company. DOI: 10.1183/09031936.00002108
S.E. Wenzel has received consulting fees, advisory board fees and speaking fees from Genentech, Inc. Her total reimbursement for the past 5 years from Genentech was US$15,000. In addition, she has been reimbursed for consulting fees, advisory boards and speaking from Merck for a total of US$20,000 over 5 years. S.E. Wenzel has received consulting and speakers fees from Critical Therapeutics of US$20,000 over the past 5 years. The TENOR study is sponsored by Genentech, Inc. and Novartis Pharmaceutical. DOI 10.1183/09031936.00112107
S.E. Wenzel. In the past 3 years, S.E. Wenzel: has received consultancies from AstraZeneca, GlaxoSmithKline, Merck, Centocor, Genentech and Novartis; has served on advisory boards for AstraZeneca, GlaxoSmithKline, Merck, Novartis and Genentech; has received lecture fees from AstraZeneca, Merck and Critical Therapeutics; and has received industry-sponsored grants from Amgen. DOI: 10.1183/09031936.00155307
J. Wharton has received an educational grant, honoraria and funds towards travel expenses from Pfizer Global Research & Development. DOI: 10.1183/09031936.00124007
J.H. Wildhaber has given lectures for AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme and Nycomed, and has been a national and international advisor for Nycomed and Merck Sharp & Dohme. He has received research grants from AstraZeneca, GlaxoSmithKline and Merck Sharp & Dohme. DOI: 10.1183/09031936.00002108
M.R. Wilkins has received travel reimbursement, lecture fees and/or consulting fees from Pfizer, Actelion and Encysive. M.R. Wilkins has no stocks or other financial interest in companies that might have any interest or benefit from contents dealt with in the author’s manuscript. DOI: 10.1183/09031936.00124007
J. Wilson received funding to attend scientific meetings from AstraZeneca Australia Pty Ltd and GlaxoSmithKline Australia Pty Ltd. DOI: 10.1183/09031936.00119307
W. Windisch. The study was supported by “Werner und Müller Medizintechnik®” (Bundesrepublik, Germany). DOI 10.1183/09031936.00066407
S. Wöhrl has received an educational grant from Merck Sharp & Dohme Austria, and fees for speaking from ALK-Abelló and AESCA Pharma. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
A. Woodcock is the inventor on a patent describing the novel methods for cough detection and monitoring, filed by the University Hospital of South Manchester (UK). A. Woodcock has an industrial collaboration and license agreement with Vitalograph UK Ltd to develop a commercial cough monitoring system (Vitalojak). DOI: 10.1183/09031936.00052008
W
Back to Top
Y
Back to Top
H. Yamasawa. Edaravone was a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). DOI : 10.1183/09031936.00164407
D.H. Yates. The research group headed by D.H. Yates received the Actelion Endothelin Research Award for a research project into pulmonary hypertension in 2006. DOI: 10.1183/09031936.00160307
R.P. Young is Chief Scientific Officer for Synergenz Biosciences Ltd (Auckland, New Zealand), which part funded the author’s study. The author also has stocks in Synergenz Bioscience Ltd. DOI 10.1183/09031936.00093908
S. Young is an employee of AstraZeneca and holds shares in the company. DOI: 10.1183/09031936.00125307
Z
Back to Top
S. Zakynthinos. The author’s study was supported in part by Pfizer Inc. (prot. no: 205.347) and by Boehringer Ingelheim. DOI: 10.1183/09031936.00155207
M. Zehnder. The ultrasound equipment used in the author’s study was made available by Toshiba and the pulse oximeter by Leuag (both Switzerland). DOI: 10.1183/09031936.00166407
C. Zeitz received the Retinitis pigmentosa prize 2006. She received funds from VELUX and received funds for a member of staff from Hartmann Müller Foundation, Zurich. The author’s study was supported by an unrestricted grant from AstraZeneca (Zug, Switzerland). DOI 10.1183/09031936.00132707
Y. Zhang. The author’s study was supported by operating funds provided by GlaxoSmithKline of Canada. DOI: 10.1183/09031936.00167007
J-P. Zock. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
T. Zuberbier. The Soluprick study allergens were donated by ALK Denmark and Spain. DOI 10.1183/09031936.00039208
M. Zureik has received an unrestricted educational grant from Boehringer Ingelheim. The author’s study was supported by unrestricted grants from Boehringer Ingelheim France (Reims, France) and Pfizer, Inc. Lob Conseil organised the logistics and tracking missing data. Theriamis undertook the data management. There are no relations with the tobacco industry.DOI: 10.1183/09031936.00129507
Back to Top
Copyright © 2008 by the European Respiratory Society.
HOME
HELP
FEEDBACK
SUBSCRIPTIONS
ARCHIVE
SEARCH